hydroxyurea has been researched along with Bone Cancer in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Osteosarcoma cells were treated with hydroxyurea to investigate the expression pattern of TET proteins in these cells." | 7.91 | Hydroxyurea promotes TET1 expression and induces apoptosis in osteosarcoma cells. ( Ma, C; Teng, S; Yi, C; Yu, Y, 2019) |
| "Hydroxyurea (HU) is a ribonucleotide reductase inhibitor which blocks DNA excision-repair by the depletion of intracellular ribonucleotides." | 6.67 | A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. ( Carmichael, J; Ganesan, TA; Harris, AL; Philip, PA; Tonkin, K, 1994) |
| " Osteosarcoma cells were treated with hydroxyurea to investigate the expression pattern of TET proteins in these cells." | 3.91 | Hydroxyurea promotes TET1 expression and induces apoptosis in osteosarcoma cells. ( Ma, C; Teng, S; Yi, C; Yu, Y, 2019) |
| "Hydroxyurea (HU) is a ribonucleotide reductase inhibitor which blocks DNA excision-repair by the depletion of intracellular ribonucleotides." | 2.67 | A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. ( Carmichael, J; Ganesan, TA; Harris, AL; Philip, PA; Tonkin, K, 1994) |
| "Thirty-nine patients with head and neck cancer were entered into Phase I-II study of simultaneous radiation therapy with continuous infusion fluorouracil at 800 mg/m2/day and escalating doses of hydroxyurea." | 2.67 | Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1991) |
| " Furthermore, the non-cytolytic and non-cytotoxic metronomic hydroxyurea dosage increased the biological therapy outcome by strengthening antitumor capability." | 1.72 | A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness. ( Borghetto, V; Costanzo, E; Di Bella, G; Di Bella, L; Moscato, I, 2022) |
| "Bloom Syndrome is an autosomal recessive cancer-prone disorder caused by mutations in the BLM gene." | 1.35 | BLAP18/RMI2, a novel OB-fold-containing protein, is an essential component of the Bloom helicase-double Holliday junction dissolvasome. ( Ali, AM; Andreassen, PR; Busygina, V; Du, CH; Fan, Q; Meetei, AR; Raynard, S; Singh, TR; Sung, P, 2008) |
| "mm." | 1.25 | Hydroxyurea in stage D carcinoma of the prostate: a pilot study. ( Cromie, W; Lerner, H; Longo, S; Malloy, T, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Di Bella, G | 1 |
| Di Bella, L | 1 |
| Borghetto, V | 1 |
| Moscato, I | 1 |
| Costanzo, E | 1 |
| Campbell, AE | 1 |
| Ferraz Franco, C | 1 |
| Su, LI | 1 |
| Corbin, EK | 1 |
| Perkins, S | 1 |
| Kalyuzhnyy, A | 1 |
| Jones, AR | 1 |
| Brownridge, PJ | 1 |
| Perkins, ND | 1 |
| Eyers, CE | 1 |
| Teng, S | 1 |
| Ma, C | 1 |
| Yu, Y | 1 |
| Yi, C | 1 |
| Singh, TR | 1 |
| Ali, AM | 1 |
| Busygina, V | 1 |
| Raynard, S | 1 |
| Fan, Q | 1 |
| Du, CH | 1 |
| Andreassen, PR | 1 |
| Sung, P | 1 |
| Meetei, AR | 1 |
| Mao, FJ | 1 |
| Sidorova, JM | 1 |
| Lauper, JM | 1 |
| Emond, MJ | 1 |
| Monnat, RJ | 1 |
| Duensing, A | 1 |
| Liu, Y | 1 |
| Spardy, N | 1 |
| Bartoli, K | 1 |
| Tseng, M | 1 |
| Kwon, JA | 1 |
| Teng, X | 1 |
| Duensing, S | 1 |
| Kim, JM | 1 |
| Kakusho, N | 1 |
| Yamada, M | 1 |
| Kanoh, Y | 1 |
| Takemoto, N | 1 |
| Masai, H | 1 |
| Philip, PA | 1 |
| Carmichael, J | 1 |
| Tonkin, K | 1 |
| Ganesan, TA | 1 |
| Harris, AL | 1 |
| van Oijen, MG | 1 |
| Medema, RH | 1 |
| Slootweg, PJ | 1 |
| Rijksen, G | 1 |
| Donelli, MG | 1 |
| Colombo, T | 1 |
| Broggini, M | 1 |
| Garattini, S | 1 |
| Wollner, N | 1 |
| Lieberman, P | 1 |
| Exelby, P | 1 |
| D'angio, G | 1 |
| Burchenal, J | 1 |
| Fang, S | 1 |
| Murphy, ML | 1 |
| Salmon, SE | 1 |
| Durie, BG | 1 |
| Lerner, H | 1 |
| Malloy, T | 1 |
| Cromie, W | 1 |
| Longo, S | 1 |
| Haraf, DJ | 1 |
| Vokes, EE | 1 |
| Panje, WR | 1 |
| Weichselbaum, RR | 1 |
2 trials available for hydroxyurea and Bone Cancer
| Article | Year |
|---|---|
A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dacarbazine; Female; Ga | 1994 |
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 1991 |
12 other studies available for hydroxyurea and Bone Cancer
| Article | Year |
|---|---|
A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness.
Topics: Antioxidants; Bone Neoplasms; Butyric Acid; Humans; Hydroxyurea; Melatonin; Osteosarcoma; Tretinoin | 2022 |
Temporal modulation of the NF-κB RelA network in response to different types of DNA damage.
Topics: Amino Acid Motifs; Amino Acid Sequence; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Chromatography, | 2021 |
Hydroxyurea promotes TET1 expression and induces apoptosis in osteosarcoma cells.
Topics: 5-Methylcytosine; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Ce | 2019 |
BLAP18/RMI2, a novel OB-fold-containing protein, is an essential component of the Bloom helicase-double Holliday junction dissolvasome.
Topics: Amino Acid Sequence; Animals; Bloom Syndrome; Bone Neoplasms; Carrier Proteins; Cell Nucleus; Cells, | 2008 |
The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage.
Topics: Antineoplastic Agents; Bone Neoplasms; Bromodeoxyuridine; Camptothecin; Cell Growth Processes; Cell | 2010 |
RNA polymerase II transcription is required for human papillomavirus type 16 E7- and hydroxyurea-induced centriole overduplication.
Topics: Amanitins; Bone Neoplasms; Centrosome; CREB-Binding Protein; Cyclin A; Cyclin A2; Enzyme Inhibitors; | 2007 |
Cdc7 kinase mediates Claspin phosphorylation in DNA replication checkpoint.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated | 2008 |
Positivity of the proliferation marker Ki-67 in noncycling cells.
Topics: Antineoplastic Agents; Biomarkers; Bone Neoplasms; Cell Count; Cell Division; Cyclin-Dependent Kinas | 1998 |
Differential distribution of antitumor agents in primary and secondary tumors.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carcinoma 256, Walker; Cyclophosphamide; Daunorubici | 1977 |
Non-Hodgkin's lymphoma in children: results of treatment with LSA2-L2 protocol.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Neoplasms; Child; Child, Preschool; Cyclophosp | 1975 |
Cellular kinetics in multiple myeloma. A new approach to staging and treatment.
Topics: Azathioprine; Bone and Bones; Bone Neoplasms; Cell Count; Computers; Cytarabine; Diagnosis, Computer | 1975 |
Hydroxyurea in stage D carcinoma of the prostate: a pilot study.
Topics: Adenocarcinoma; Aged; Anemia; Bone Neoplasms; Chlorotrianisene; Estrogens; Humans; Hydroxyurea; Leuk | 1975 |